Next Article in Journal / Special Issue
Carbohydrate Mimetic Peptides Augment Carbohydrate-Reactive Immune Responses in the Absence of Immune Pathology
Previous Article in Journal
Risk of Prostate Cancer after Trans Urethral Resection of BPH: A Cohort and Nested Case-Control Study
Previous Article in Special Issue
Peptide Based Vaccine Approaches for Cancer—A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen
Cancers 2011, 3(4), 4139-4150; doi:10.3390/cancers3044139

Sarcoma Immunotherapy

1,* , 2
1 and 2
1 Departments of Oncology, Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA 2 Departments of Orthopaedic Surgery, Huntsman Cancer Institute at the University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA
* Author to whom correspondence should be addressed.
Received: 6 September 2011 / Revised: 19 October 2011 / Accepted: 19 October 2011 / Published: 10 November 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [184 KB, uploaded 10 November 2011]


Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential efficacy of this treatment modality. The rarity and heterogeneity of tumors of mesenchymal origin continues to be a challenge from a therapeutic standpoint. Nonetheless, sarcomas remain attractive targets for immunotherapy, as they can be characterized by specific epitopes, either from their mesenchymal origins or specific alterations in gene products. To date, standard vaccine trials have proven disappointing, likely due to mechanisms by which tumors equilibrate with and ultimately escape immune surveillance. More sophisticated approaches will likely require multimodal techniques, both by enhancing immunity, but also geared towards overcoming innate mechanisms of immunosuppression that favor tumorigenesis.
Keywords: sarcoma; immunotherapy; immunosurveillance; vaccine sarcoma; immunotherapy; immunosurveillance; vaccine
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Gouw, L.G.; Jones, K.B.; Sharma, S.; Randall, R.L. Sarcoma Immunotherapy. Cancers 2011, 3, 4139-4150.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert